KLOW

The GHK-Cu, BPC-157 and TB-500 components behave exactly as they do in GLOW - copper-driven transcription of collagen and antioxidant genes, VEGFR2 and nitric-oxide-mediated angiogenesis, and actin-sequestration-driven cell migration with reduced fibrosis. KPV is the addition, and it is the C-terminal tripeptide of alpha-MSH that blocks NF-kappaB nuclear translocation and stabilises mast cells, giving a direct anti-inflammatory action none of the other three provide. That is why KLOW is pushed for inflammatory bowel symptoms, eczema, rosacea and mast-cell-flavoured presentations rather than for cosmetic skin work. The practical catch is that KPV's best-supported route is oral, where it is absorbed intact through the PepT1 transporter and reaches the colonic epithelium, whereas in this blend it is injected subcutaneously alongside three peptides that have no reason to be taken orally. If the gut is genuinely your target, oral KPV plus oral BPC-157 makes more mechanistic sense than an injected four-way blend, and the blend's real selling point is convenience rather than delivery.

Targets: NF-kappaB nuclear translocation, Melanocortin receptor signalling and mast-cell stabilisation, Copper transport and collagen / elastin gene expression, VEGFR2 and nitric oxide signalling, G-actin sequestration and cell migration

• · Ten units from an 80 mg vial in 3 mL is 2,667 mcg of total blend, which is about 1,667 mcg GHK-Cu plus 333 mcg each of KPV, BPC-157 and TB-500. That puts KPV, BPC-157 and TB-500 all inside their usual standalone bands and GHK-Cu at the top of its own. The lower end of this range, 2,000 mcg, is roughly 7.5 units.
• · The pattern to use if you want more than four weeks of KPV coverage for a chronic inflammatory problem, since it cuts weekly copper exposure by about thirty percent without changing the per-dose amounts of anything.
• · Five units, delivering about 833 mcg GHK-Cu and 167 mcg each of the other three. Worth doing because with four peptides in one vial you have four possible sources of a reaction and no way to tell them apart after the fact.

Work out your exact syringe units →

• very commonInjection-site pain, redness and brown or blue-grey staining— The GHK-Cu component. Marks can last weeks.
• uncommonMetallic taste or nausea— Copper load signal. Back the dose off.
• uncommonFlushing or transient itch— Sometimes attributed to the KPV component acting on mast cells, though with four peptides in the vial you cannot actually attribute it.
• uncommonLoose stools or transient gut upset in the first week— Usually settles. Common when the blend is being used for gut symptoms in the first place.
• uncommonFatigue or headache on longer runs— Typically week three onward and usually attributed to copper-zinc imbalance.
• rareCopper accumulation and disturbed copper-zinc balance— Theoretical at these doses but the specific reason the cycle is short.

• Wilson's disease or any impairment of copper excretion - the hard stop for any GHK-Cu-containing blend.
• Known copper allergy or hypersensitivity.
• Active or recent malignancy - GHK-Cu and BPC-157 are both pro-angiogenic.
• Pregnancy and breastfeeding.
• Drug-tested athletes - BPC-157 and TB-500 are WADA-prohibited.

• redundantkpv — The vial already contains 10 mg of KPV. Adding standalone oral or injectable KPV on top is double-dosing the one component people usually buy KLOW for.
• redundantghk-cu — 50 mg of GHK-Cu is already in the vial and it is the component that limits your cycle. Do not add more copper peptide.
• redundantbpc-157 — Running standalone BPC-157 alongside KLOW is double-dosing. Buy the components separately if you need more of one.
• redundanttb-500 — Adding a standard 2 mg twice-weekly TB-500 course on top of daily KLOW pushes weekly TB-500 past anything with data behind it.
• redundantthymosin-beta-4 — Same actin-sequestration target as the TB-500 already in the vial.
• redundantglow — KLOW is GLOW plus KPV. Running both means taking the three shared peptides twice for no benefit.
• cautionZinc supplementation — Needed to keep the copper-zinc ratio from drifting on a run, but very high simultaneous doses will blunt copper uptake. 15 to 30 mg daily is the usual compromise.

• · Read the vial label and recompute mg/mL for every new vendor - the same blend name does not guarantee the same amounts.
• · Serum copper and ceruloplasmin if you run past eight weeks or go straight into another cycle.
• · Track the actual gut or skin symptom you are treating with a simple daily score, since inflammatory symptoms fluctuate on their own and are easy to misattribute.
• · Rotate injection sites and watch for staining that is not resolving.

No component is an approved drug for human use and the blend is sold purely as a research chemical. In April 2026 the FDA removed BPC-157, TB-500, GHK-Cu and KPV from the Category 2 bulk drug substances list, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, TB-500 and KPV for the 503A Bulks List; that vote is non-binding, the FDA has not acted on it, and GHK-Cu was not included. A four-peptide blend of unapproved substances is not compoundable in any case. BPC-157 and TB-500 are WADA-prohibited.

• Dalmasso et al., PepT1-mediated tripeptide KPV uptake and attenuation of experimental colitis (preclinical)
• Pickart & Margolina 2018, regenerative and protective actions of the GHK-Cu peptide (review)
• Sikiric et al., BPC 157 cytoprotection reviews in gut and soft-tissue models (review)
• Vendor certificates of analysis and labels for 80 mg KLOW blend vials (other)

KPV is the only reason to choose KLOW over GLOW, so it deserves the detail. The classical assumption was that alpha-MSH fragments work through melanocortin receptors. Dalmasso's 2008 Gastroenterology work made a stronger and more useful claim: KPV's anti-inflammatory effect in intestinal epithelial and immune cells is PepT1-dependent and does not require melanocortin receptors at all. Nanomolar concentrations of KPV inhibited NF-kappaB activation, and the peptide was shown entering cells through PepT1 - a transporter that is minimally expressed in healthy colon but is upregulated in inflamed colonic epithelium. That is an unusually elegant piece of pharmacology: the transporter that lets the drug in is induced by the disease you are treating, so uptake is highest exactly where inflammation is worst. That mechanism is also the single strongest argument against this product's delivery route. Injecting KPV subcutaneously does not put it in the intestinal lumen where PepT1-expressing epithelium is waiting. You get systemic KPV, which is a plausible but far less characterised proposition, and you give up the targeted-uptake mechanism that made the colitis data compelling. Kannengiesser's murine IBD work and later oral nanoparticle delivery studies both reinforce that the interesting KPV pharmacology is luminal. Downstream of NF-kappaB blockade, KPV reduces transcription of TNF-alpha, IL-6, IL-1beta and IL-8 and reduces neutrophil recruitment. It also has reported mast-cell stabilising and direct antimicrobial activity inherited from the alpha-MSH lineage. Clinically that translates into the pattern users describe - itch, flush and inflammatory skin or gut symptoms settling within one to two weeks, before anything structural could have changed. That timeline is consistent with signalling suppression rather than repair, which is worth knowing because it means the effect is likely to disappear when you stop. The other three components behave exactly as in GLOW. GHK-Cu supplies copper as a cofactor for lysyl oxidase and superoxide dismutase and acts as a broad transcriptional modulator; BPC-157 works through VEGFR2-Akt-eNOS with no identified receptor; TB-500 sequesters G-actin. The pharmacological logic of adding an NF-kappaB blocker to a repair stack is genuinely sound - you are suppressing the signalling that perpetuates injury while driving matrix synthesis - and it has never been tested.

The first thing that goes wrong is that people buy KLOW for gut inflammation and inject it, which is the one route KPV's evidence does not support. The colitis data is oral, the uptake transporter is intestinal, and the transporter is upregulated by the disease itself. Subcutaneous KPV is not that experiment. If you want the KPV mechanism the papers describe, you want it in your gut, not your abdominal fat. The second is attribution failure. Four peptides in one vial means four suspects for every reaction. Flushing could be KPV mast-cell activity or the copper. Loose stools could be BPC-157 or the underlying condition you are treating. Fatigue in week three could be copper-zinc drift or nothing. You cannot resolve any of it, and the only corrective action the product allows is to take less of all four or stop. The third is the label. Vendors are genuinely inconsistent about whether the milligram figure on an 80 mg KLOW vial is the total or per component. Getting it wrong changes your dose four-fold. Confirm from the certificate of analysis before you calculate anything, and if there is no per-component breakdown, you do not know your copper dose. The fourth is running it for months because a chronic inflammatory condition is a chronic problem. Copper does not care that your colitis is chronic. Four weeks on with two to four off is the cap, and it is set by the 50 mg of GHK-Cu in the vial, not by anything KPV does. The people who need months of KPV should not be getting it from this product. The fifth is stopping a working therapy. This is the one that puts people in hospital. A blend that suppresses NF-kappaB signalling will make symptoms better before it makes anything else better, and that feeling is a very poor guide to what the mucosa is doing. Keep the objective marker in the loop and do not touch prescribed treatment on the strength of feeling well. The sixth is treating undiagnosed symptoms. Unexplained bleeding, weight loss or a change in bowel habit needs investigating before it gets a peptide thrown at it. A blend that reduces inflammatory symptoms is very good at making a delayed diagnosis feel reasonable at the time.

1. 1.333 mgDays 1 to 5 — Five units from an 80 mg vial in 3 mL - about 833 mcg GHK-Cu and 167 mcg each of KPV, BPC-157 and TB-500. Worth doing properly here because four peptides means four candidates for any reaction and no way to tell them apart afterwards.
2. 2.667 mgDays 6 to 14 — Ten units - roughly 1,667 mcg GHK-Cu with 333 mcg each of KPV, BPC-157 and TB-500. Every component except GHK-Cu is comfortably inside its standalone band; GHK-Cu is at the top of its. This is the working dose and there is no good argument for exceeding it.
3. 2.667 mgWeeks 3 to 4 — Hold. This is where inflammatory symptoms should have shifted if they are going to. If your gut or skin symptom is unchanged by the end of week four, the blend is not working for you and raising the dose only raises the copper.
4. 2.667 mgWeeks 4 to 8 if continuing — Switch to five days on, two off. Cuts weekly copper about thirty percent without changing any per-dose amount, which is the only lever the fixed ratio gives you. If you need more than eight weeks of KPV coverage for a chronic inflammatory problem, stop using the blend and run oral KPV separately.

• PepT1 (SLC15A1) intestinal peptide transporter

  The uptake route for KPV, and the reason oral dosing is the evidence-based one. PepT1 is upregulated in inflamed colonic epithelium, so uptake concentrates where the disease is. Subcutaneous injection bypasses this entirely.

• NF-kappaB signalling pathway

  KPV inhibits NF-kappaB activation at nanomolar concentrations, blocking nuclear translocation and reducing transcription of TNF-alpha, IL-6, IL-1beta and IL-8. This is the mechanism KLOW is bought for and the one GLOW does not have.

• Melanocortin receptors (MC1R and MC3R-MC5R)

  The historically assumed target for alpha-MSH fragments. Dalmasso's work indicates KPV's intestinal anti-inflammatory effect is melanocortin-receptor-independent, which matters because it means KPV should not produce the pigmentation effects of full alpha-MSH agonists.

• Mast cells

  Reported stabilisation, inherited from the alpha-MSH literature. This is the basis for using KLOW in histamine and mast-cell-flavoured presentations, and it is the least well-evidenced of KPV's claimed actions.

• Lysyl oxidase and superoxide dismutase 1 (copper-dependent)

  The GHK-Cu arm supplying copper as an obligate enzyme cofactor for collagen cross-linking and antioxidant capacity.

• VEGFR2 and the nitric oxide system

  The BPC-157 arm. Angiogenesis and cytoprotection downstream of VEGFR2-Akt-eNOS, with no demonstrated direct receptor binding.

• G-actin

  The TB-500 arm. Actin monomer sequestration driving cell migration and reduced fibrosis.

Days 1 to 3: injection-site reaction from the copper, and for some people a transient flush or itch attributed to the KPV arm. Nothing therapeutic yet. Week 1: this is when the inflammatory symptoms move if they are going to. Urgency, bloating, itch and skin flushing are the fastest responders, which is consistent with signalling suppression rather than tissue repair. Transient loose stools in the first few days are common and usually settle. Weeks 1 to 2: the honest evaluation window for the KPV arm. NF-kappaB blockade is a fast mechanism. If nothing about your inflammatory symptom has changed by the end of week two, this blend is unlikely to be the answer for you. Weeks 2 to 4: soft-tissue and gut repair effects from the BPC-157 arm, plus whatever the copper-driven matrix work contributes. Copper-related fatigue and headache also tend to appear around week three if they are going to. Weeks 4 to 8: skin quality changes from the GHK-Cu arm become assessable, on the same slow timeline as GLOW. Mucosal repair, if it is happening, is in this window and is not something you can feel - it is a calprotectin question. After stopping: the anti-inflammatory effect fades quickly, within days to a couple of weeks, because you removed a signalling brake rather than fixed a driver. That rebound is expected and is not evidence the blend was doing something profound. Anything gained structurally persists longer.

The copper rules from GLOW apply unchanged: 15 to 30 mg zinc daily through the run and the break, no copper-containing multivitamin, no standalone GHK-Cu on top, no stacking with GLOW or Wolverine. The KLOW-specific decision is about KPV and route. If your target is the gut lining, the mechanistically correct move is oral KPV, ideally in a delayed-release form that gets past the stomach, because PepT1 uptake in inflamed colonic epithelium is the mechanism the evidence rests on. Running oral KPV alongside injected KLOW is not double-dosing in any dangerous sense - KPV has an unremarkable safety profile and the doses involved are small - but it is an admission that you bought the wrong product. The cleaner version is oral KPV plus oral BPC-157, with no copper at all, which can run for months instead of weeks. For a diagnosed inflammatory bowel disease, the only stacking note that matters is negative. There is no interaction data between these peptides and mesalazine, azathioprine, or any biologic. The real risk is behavioural: people feel better in week two because NF-kappaB signalling is suppressed, taper their proven therapy, and relapse. Symptom relief on this blend is not remission and calprotectin will tell you the difference. Glutamine, zinc carnosine and a low-fermentation diet are the boring adjuncts with better evidence than anything in this vial for gut mucosal work, and none of them conflict. Antihistamines and mast cell stabilisers overlap conceptually with the KPV arm but do not conflict pharmacologically. If you are using KLOW for a mast-cell presentation and already on a stabiliser, you will find it very hard to attribute any change to the peptide. GH secretagogues, testosterone and the usual performance stacks have no mechanistic conflict with any of the four components.

Against GLOW: the only difference is 10 mg of KPV, and that difference is the entire reason to pay more. If your target is inflammation, gut symptoms, eczema, rosacea or a mast-cell presentation, KLOW is the right one of the two. If your target is skin quality, hair or a tendon, the KPV is doing nothing for you and GLOW is cheaper. Against oral KPV plus oral BPC-157: for a gut problem this is straightforwardly the better protocol and it is not close. You get the PepT1 uptake mechanism the evidence actually describes, you get both components delivered to the tissue you are treating, you can run it for months instead of four weeks, you avoid injecting a copper complex you have no gut-related reason to take, and it costs less. The only thing KLOW offers over it is that it is one purchase and one injection. Against standalone KPV: standalone KPV is dose-flexible, cheap, has an unremarkable safety profile, and can be run orally for as long as you like. KLOW ties it to a copper cycle limit for no mechanistic reason. Against BPC-157 plus KPV blend: that two-peptide product is KLOW's gut-directed half without the copper or the TB-500, available orally, with no cycle cap driven by a heavy metal. For gut work it is the better-designed product of the two. Against actual IBD treatment: this is not a competitor to mesalazine, a thiopurine or a biologic, and nobody has ever run the comparison. It is an adjunct with mouse data, and the failure mode of treating it as a substitute is severe.

$70–$160/month. An 80 mg vial in 3 mL gives roughly thirty ten-unit doses, so about one vial per month at the standard protocol. Grey-market pricing has generally run slightly above GLOW for the extra component. Add ten to twenty dollars for water, syringes and zinc, and add a calprotectin test if you are using it for gut symptoms, which is the single most useful thing you can spend money on with this product. These are observed market ranges, not figures verified in this session.

• ?The four-to-one-to-one-to-one ratio has no published basis. It appears to be GLOW's ratio with KPV added at the same share as the two repair peptides.
• ?No human pharmacokinetic data exists for KPV by any route. The under-one-hour clearance figure quoted for it is a reasonable inference from its size and lack of protective modification, not a measured human value.
• ?Whether subcutaneously injected KPV reproduces any of the anti-inflammatory effects demonstrated for oral KPV is unknown. The mechanism that made the colitis data compelling is specifically intestinal, and this product bypasses it.
• ?No verified binding affinity figures were resolved for KPV at melanocortin receptors or for its PepT1 interaction, so those fields are left empty.
• ?The mast-cell stabilisation attributed to KPV is inherited from the broader alpha-MSH literature rather than demonstrated for the tripeptide specifically, and I did not resolve a primary source for it.
• ?Molecular weights for all four components are omitted deliberately - none was verified in this session.
• ?The faecal calprotectin guidance is standard gastroenterology practice, not a KLOW-specific finding. No study has ever measured calprotectin on this blend or any of its components in humans.
• ?The copper cycle cap is precautionary reasoning from copper physiology and biliary excretion, not measurement of copper status on this product.
• ?No human trial of KLOW, or of any two of its four components together, exists. The trials array is empty for that reason.
• ?Cost ranges are general market observation and were not verified against current vendor pricing this session.
• ?Component sequences in the modifications array are established chemistry but were not independently resolved this session, hence verified false.

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D, Gastroenterology, 2008 · PMID 18061177

  The single most important paper for this blend and the one that justifies KPV's inclusion. Established that nanomolar KPV inhibits NF-kappaB activation, that uptake occurs via the PepT1 transporter in epithelial and immune cells, and that oral KPV reduces colitis severity in mice - explicitly without requiring melanocortin receptors. Read it and you will understand why oral KPV has a better argument than the injected KPV in this vial.

• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T, Inflammatory Bowel Diseases, 2008 · PMID 18092346

  Independent murine IBD data supporting the KPV anti-inflammatory claim from a different group. Two groups reaching the same conclusion in the same year is the strongest thing this blend has going for it, and it is still mice.

• Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D, Molecular Therapy, 2017 · PMID 28143741

  Included because it shows where the serious KPV research actually went - toward targeted oral colonic delivery, not toward subcutaneous injection. The people who understand this molecule best are trying to get more of it into the gut lumen, which is the opposite of what this blend does.

• alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs Luger TA, Brzoska T, Annals of the Rheumatic Diseases, 2007 · PMID 17934097

  Background on the alpha-MSH fragment class that KPV belongs to, including the skin and immune applications that underpin KLOW's use for eczema and rosacea.

• alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW, Journal of Investigative Dermatology, 2004 · PMID 15102092

  Human keratinocyte signalling data for KPV specifically, which is the closest thing to a rationale for the skin indications this blend is sold on.

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, Margolina A, International Journal of Molecular Sciences, 2018 · PMID 29986520

  Reference review for the GHK-Cu component, which is still 50 of the 80 mg in the vial and still the thing that caps your cycle.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M, Frontiers in Pharmacology, 2022 · PMID 36588717

  The only ADME data on BPC-157 and the source of the half-life and bioavailability figures quoted in this record.

• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Sikiric P, et al, Frontiers in Pharmacology, 2021 · PMID 34267654

  The BPC-157 mechanism review, from the group that produced most of the BPC-157 literature.

• Advances in the basic and clinical applications of thymosin beta4 Goldstein AL, Kleinman HK, Expert Opinion on Biological Therapy, 2015 · PMID 26096726

  Reference review for the TB-500 arm, about the full-length protein rather than the marketed fragment.